# Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19

> **NCT04358588** · — · NO_LONGER_AVAILABLE · sponsor: **Bellerophon**

## Conditions studied

- Coronavirus Infection
- COVID-19
- Pneumonia, Viral

## Interventions

- **DRUG:** iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System

## Key facts

- **NCT ID:** NCT04358588
- **Lead sponsor:** Bellerophon
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358588, "Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04358588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*